Vor Biopharma Inc. Debt Securities, Available-for-sale, Change in Present Value, Expense (Reversal)
Vor Biopharma Inc. (VOR) reported Debt Securities, Available-for-sale, Change in Present Value, Expense (Reversal) of $0 for the 3-month period ending 2022-03-31, per its 10-Q filed 2022-05-12.
Discontinued › Operating Expenses
us-gaap:DebtSecuritiesAvailableForSaleChangeInPresentValueExpenseReversal · last filed 2022-05-12
- Vor Biopharma Inc. debt securities, available-for-sale, change in present value, expense (reversal) for the quarter ending 2022-03-31 was $0.00.
| Period end | Debt Securities, Available-for-sale, Change in Present Value, Expense (Reversal) 3 month |
|---|---|
| 2022-03-31 | $0.00 10-Q · filed 2022-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |